<SEC-DOCUMENT>0001104659-16-128214.txt : 20160620
<SEC-HEADER>0001104659-16-128214.hdr.sgml : 20160620
<ACCEPTANCE-DATETIME>20160620084923
ACCESSION NUMBER:		0001104659-16-128214
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20160620
DATE AS OF CHANGE:		20160620

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-211555
		FILM NUMBER:		161721395

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		STREET 2:		BUILDING ONE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		STREET 2:		BUILDING ONE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELECTA BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001453687
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		STREET 2:		BUILDING ONE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-923-1400

	MAIL ADDRESS:	
		STREET 1:		480 ARSENAL STREET
		STREET 2:		BUILDING ONE
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>a15-22910_12fwp.htm
<DESCRIPTION>FWP
<TEXT>


<html>
<head>




  </head>
<body link=blue bgcolor="white" lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Issuer Free Writing Prospectus dated June&nbsp;20, 2016</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Filed Pursuant to Rule&nbsp;433</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Relating to the Preliminary Prospectus dated June&nbsp;8, 2016 and</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Registration Statement No.&nbsp;333-211555</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="342" height="85" src="g2291012bgi001.jpg" alt="GRAPHIC"></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Update to Preliminary Prospectus</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Issued June&nbsp;8, 2016</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This free writing prospectus relates only to the initial public offering of shares of common stock of Selecta Biosciences,&nbsp;Inc. (the &#147;Company&#148;) and should be read together with the preliminary prospectus (the &#147;Preliminary Prospectus&#148;), subject to completion, dated June&nbsp;8, 2016, included in Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1 (File No.&nbsp;333-211555), relating to the Company&#146;s initial public offering.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On June&nbsp;20, 2016, the Company filed Amendment No.&nbsp;2 to the Registration Statement on Form&nbsp;S-1 (&#147;Amendment No.&nbsp;2&#148;), which may be accessed through the following link: <a href="http://www.sec.gov/Archives/edgar/data/1453687/000104746916013886/a2228960zs-1a.htm">http://www.sec.gov/Archives/edgar/data/1453687/000104746916013886/a2228960zs-1a.htm</a>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information set forth below from Amendment No.&nbsp;2 reflects updates to disclosures for a serious adverse event recently reported to the Company, the approval of the Company&#146;s common stock for listing on The NASDAQ Global Market and updates to disclosures relating to the Company&#146;s equity incentive plans.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Update to &#147;Risk factors&#148; and Phase 1b clinical trial disclosure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">After the date of the Preliminary Prospectus, a serious adverse event in the Phase 1b clinical trial of SEL-212 was observed.&#160; This serious adverse event was in addition to the two serious adverse events previously disclosed in the Preliminary Prospectus.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accordingly, the disclosures set forth on page&nbsp;21 of the Preliminary Prospectus in the second paragraph under the section entitled &#147;Risk factors&#151;Risk related to the discovery, development and regulatory approval of our product candidates&#151;Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates&#148; and on page&nbsp;133 of the Preliminary Prospectus under the last paragraph of the section entitled &#147;Business&#151;Our SVP programs to induce antigen-specific tolerance&#151;SEL-212 for the treatment of refractory and chronic tophaceous gout&#151;Clinical development&#151;Phase 1b clinical trial&#148; have been updated to include the following:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of June&nbsp;16, 2016, there have been three serious adverse events, or SAEs, in the Phase 1 clinical trials.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A third observation was classified by the principal investigator on June&nbsp;15, 2016 as an SAE after a 59 year-old male from Cohort #7 (SVP-Rapamycin Cohort) of the Phase 1b clinical trial developed stomatitis approximately seven days after being dosed with 0.5 mg/kg of SVP-Rapamycin, the highest dose of SVP-Rapamycin in the SVP-Rapamycin Cohorts of the Phase 1b clinical trial, and experienced 4.3 kg of weight loss.&#160; Stomatitis is a form of mouth sores and inflammation of the mouth and lips that often limits food intake and, according to the label for rapamycin, is a common adverse reaction to rapamycin itself.&#160; This subject was treated with oral over-the-counter and topical antihistamines followed by a steroid gel. As of June&nbsp;16, 2016, the principal investigator indicated that the subject&#146;s stomatitis was improving. The principal investigator classified this third SAE as having been possibly related to the study drug, SVP-Rapamycin.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-22910-12\task7995465\22910-12-bg.htm',USER='105538',CD='Jun 20 18:14 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NASDAQ Global Market</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s common stock has been approved for listing on The NASDAQ Global Market under the symbol &#147;SELB.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Equity award plans</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The disclosure in the Preliminary Prospectus has been updated as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>819,460 shares are available for future issuance under the 2016 Incentive Award Plan (pages&nbsp;10, 72 and 76);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the option to purchase up to 123,076 shares granted to Dr.&nbsp;Cautreels on December&nbsp;4, 2015 vests in 48 equal monthly installments (pages&nbsp;186 and 187);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>2,213,412 shares are reserved for future issuance under the 2008 Equity Incentive Plan (page&nbsp;194); and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>1,723,704 options are outstanding and 1,046,380 options are vested as of May&nbsp;31, 2016 (pages&nbsp;206 and 211).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Company has filed a registration statement (including the Preliminary Prospectus) with the Securities and Exchange Commission (the &#147;SEC&#148;) for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus in that registration statement for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC website at <i>www.sec.gov</i>. Alternatively, a copy of the Preliminary Prospectus may be obtained from the offices of: UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, (888) 827-7275; or Stifel, Nicolaus&nbsp;&amp; Company,&nbsp;Incorporated, Attention: Syndicate, One Montgomery Street, Suite&nbsp;3700, San Francisco, CA 94104, or by telephone at (415) 364-2720 or by email to <i>syndprospectus@stifel.com</i>.&#160; You may obtain a copy of Amendment No.&nbsp;2 at </font></b><a href="http://www.sec.gov/Archives/edgar/data/1453687/000104746916013886/a2228960zs-1a.htm">http://www.sec.gov/Archives/edgar/data/1453687/000104746916013886/a2228960zs-1a.htm</a><b>.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-22910-12\task7995465\22910-12-bg.htm',USER='105538',CD='Jun 20 18:14 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g2291012bgi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2291012bgi001.jpg
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M"=1H(8)90Y(/69$U[VK/YI5U&:JV[E/X]-E5GE3RAGX<X0&W7EL?7/@6'K<
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M;QN0TQ'W&R[IG]9:FNY&>]FLCQN7:25+L^/BI5I)>9J#Q5A,_A6%FCFB@_\
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MP$0C X",)]@3CQX_;MMZZZ^IJJRBJZVDI:\*IIZ< .JJJNN&A"KZVMKAH@P
M 0QV1CBAAB0PC"C01LA@@BCBB8UC&M3]RL8JJJL8J_>JM15_:JIU]=?+_=JI
MW[>9/+W3ZIYOS47]Z]6R2Q+,26))))))).Y))]DD^R3[)ZK          V
M]  #T !Z 'XZH"_$N[6%SGQ!:/7]>5!,-I;16$XQ8##R))\GDV9W&19_:0S-
M8Y6QE.I+?$W2Q^STB= KD153O/M\-AK'\BO#D'R\D)(BMP[MV?G#")(E;(15
MT4U/K6L5%<G]Y UV$GR0/3NU?F)%:Y47OU3/\3#:@^X>?G,/9(9C+&KL-Z[
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MW^%B:Q5[M@D_:'*%:]?E]KVYZ\9_OZG77.JJVC=-9'.3\6EAC\-"!CM\K(3
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MKQ*!B0  =QOZF4HM0DR9E:&G$L[2RV8)ZKQ"N[Q3"6"Q%%8C=)(V3QO$'9@
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1$L6.\DTCOMOQ4$(@5%51_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
